Furthermore, the MUC1 intracellular domain has become the focus of therapeutic strategies, and MUC1 peptide antagonists have yielded promising results as anti-tumor therapies in mouse models of breast and prostate cancer [52], [53], [54], [55]. This evidence concerns the gene MUC1 and prostate cancer.